NCT05748093 Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With Cobicistat
| NCT ID | NCT05748093 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Maastricht University Medical Center |
| Condition | Non-small Cell Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-04-01 |
| Primary Completion | 2026-06-01 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The goal of this clinical trial is to assess the feasibility of pharmacokinetically boosting osimertinib using cobicistat in order to improve osimertinib exposure in individual patients with advanced NSCLC (Non-Small Cell Lung Cancer) with mutated EGFR (Epidermal Growth Factor Receptor). The main questions it aims to answer are: * Cohort 1: Does concurrent use of osimertinib and cobicistat allow for osimertinib weekly intake reductions? If so, how much can the intake be reduced while retaining clinically effective exposure? * Cohort 2: Does concurrent use of osimertinib and cobicistat allow for improved penetration of osimertinib in the central nervous system, in patients with CNS (central nervous system) oligoprogression? Participants who are taking osimertinib in regular care will receive cobicistat in addition to their other medication. They will undergo blood sampling to measure the amount of osimertinib in blood, and measure the effect of boosting. Additionally, in cohort 1 patients will be dose-reduced if their exposure levels allow.
Eligibility Criteria
Inclusion Criteria: In order to be eligible to participate in this cohort 1, a subject must meet all of the following criteria: * The patient is set to receive osimertinib 80 mg QD as part of their standard treatment plan * The patient has a World Health Organization (WHO) Performance Status (PS) of ≤2. * The patient is 18 years or older * The patient is able and willing to sign informed consent * The patient is able and willing to undergo blood sampling * The patient has non-squamous advanced EGFR-mutated NSCLC with no signs of imminent progression (CT confirmed). If the patient does have signs of progression, they are only eligible if their treating physician deems the treatment to be appropriate beyond progression. * The patient consents to their blood being analysed for CYP3A-genotype In order to be eligible to participate in this cohort 2, a subject must meet all of the following criteria: * The patient is set to receive osimertinib 80 mg QD as part of their standard treatment pla
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.